Plain-English translation of NCT06250257 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing whether bromocriptine, a medication that affects hormone levels in the body, can help treat dilated cardiomyopathy—a condition where the heart becomes enlarged and doesn't pump blood as well as it should. The study is designed for women of reproductive age who have been diagnosed with this heart condition. Researchers believe that hormones may play a role in how this disease develops, and this medication might help improve heart function when combined with standard heart medications.
Dilated cardiomyopathy is a serious condition that can lead to heart failure and sometimes requires a heart transplant. Recent research suggests that hormones, particularly prolactin, may contribute to the development of this condition in women. This trial exists to see whether targeting these hormonal factors with this medication could offer women a new treatment option that improves their heart health and outcomes.
You likely qualify if…
You likely don't qualify if…
If you join this study, you will be randomly assigned to either receive the medication plus your regular heart treatments, or to receive a placebo (a pill with no active ingredient) plus your regular heart treatments. You will take your assigned pill once daily for 8 weeks. The study will monitor your heart function and health throughout this period to see whether the medication helps improve your condition compared to standard treatment alone.
AI-generated summary from trial data · Jun 19, 2026 · Not medical advice
Ethiopia